doi.org
Integration of whole genome sequencing analysis with unique patient-derived models reveals clinically relevant drug targets in TFCP2 fusion-defined rhabdomyosarcoma
Abstract. Precision medicine is a likely future for all cancer treatment, but may have its greatest impact for less common, high-mortality and molecularly heterogeneous cancers. TFCP2-rearranged Rhabd...